Vanderbilt-Nigeria Building Research Capacity in HIV and Non-communicable Diseases (NCDs) (V-BRCH)

摘要 范德比尔特-尼日利亚艾滋病毒/非传染性疾病研究能力建设(‘V-BRCH’) 该计划是一种协调一致的方法，旨在建设尼日利亚调查人员成功启动和 对艾滋病毒相关的非传染性疾病实施高质量的临床试验。V-BRCH建立在由来已久的高度 尼日利亚和美国两家领先研究机构成功合作--阿米努 卡诺教学医院(AKTH)和范德比尔特大学医学中心。V-BRCH将固化一种大气 对AKTH内科教员进行艾滋病毒临床试验的持续指导和技能获取- 通过短期和中期学习机会、结对辅导安排和 指导研究项目(目标1)。我们将每年挑选三名AKTH教职员工参加 有效的每年1个月的范德比尔特研究、发展和伦理研究所(“VIRDE”)教员 纳什维尔的浓缩项目。我们每年将在尼日利亚提供两个为期两周的现场研讨会 艾滋病毒相关非传染性疾病流行病学、临床试验方法学和基金的医生和研究人员 写作。我们会在大埔大会堂物色以研究为本的初级教职员(n=8)，在下列主要范畴提供重点培训： 在临床试验管理和监管方面的需要和监督。学者们将分享最佳实践和 通过指导小组、定期举行的“正在进行的工作”会议和每月职业生涯会议吸取的经验教训 发展研讨会。将向导师-学员团队(n=10)提供竞争性种子赠款，以促进 有针对性的国内试点研究侧重于与艾滋病毒相关的非传染性疾病。对于长期培训(目标2)，我们将 支持尼日利亚巴耶罗大学/AKTH加强公共卫生硕士(公共卫生硕士)培训(总计：8 2名尼日利亚医生在范德比尔特大学获得临床调查(MSCI)理学硕士学位 科学家。我们将通过短期项目建设艾滋病毒相关非传染性疾病临床试验研究的机构能力 区域课程、工作人员发展讲习班和公共卫生公共卫生课程改进(目标3)。利用，利用 补充课程、点对点小组学习和研究网络机会，V-BRCH将 利用由外国投资委员会资助的其他培训方案在尼日利亚和撒哈拉以南非洲开展的培训活动 (南南合作机会)。V-BRCH代表着多年来在 范德比尔特和AKTH之间的研究和培训，将为可持续发展奠定基础 临床试验研究的重点是尼日利亚与艾滋病毒相关的非传染性疾病。

ABSTRACT The Vanderbilt-Nigeria Building Research Capacity in HIV/Non-communicable Diseases (NCDs) (`V-BRCH') program is a coordinated approach to build the capacity of Nigerian investigators to successfully initiate and implement high-quality clinical trials in HIV-associated NCDs. V-BRCH builds upon long-standing and highly successful collaborations between two leading research institutions in Nigeria and the United States - Aminu Kano Teaching Hospital (AKTH) and Vanderbilt University Medical Center. V-BRCH will solidify an atmosphere of continuous mentoring and skills acquisition for AKTH physician faculty in conducting clinical trials in HIV- associated NCDs via short- and medium- term learning opportunities, paired mentoring arrangements and mentored research projects (Aim 1). We will select three AKTH faculty members per year to attend the highly effective annual 1-month long Vanderbilt Institute for Research Development and Ethics (“VIRDE”) faculty enrichment program in Nashville. We will offer two 2-week, on-site workshops in Nigeria every year for physicians and research staff on HIV-associated NCD epidemiology, clinical trials methodology, and grant writing. We will identify research-oriented junior faculty staff (n=8) at AKTH for focused training in key areas of need and in clinical trials administration and regulatory oversight. Scholars will share best practices and lessons learned through mentoring panels, regular `Works in Progress' meetings, and monthly career development seminars. Competitive seed grants will be provided to mentor-mentee teams (n=10) to promote targeted in-country pilot studies focused on HIV-associated NCDs. For long-term training (Aim 2), we will support enhanced Master of Public Health (MPH) training at Bayero University/AKTH in Nigeria (total: 8 physicians) and Master of Science in Clinical Investigation (MSCI) at Vanderbilt for 2 Nigerian physician scientists. We will build institutional capacity in HIV-associated NCD clinical trials research via short-term regional courses, staff development workshops and MPH curriculum refinement (Aim 3). To take advantage of complementary courses, peer-to-peer group learning and research networking opportunities, V-BRCH will leverage training activities conducted by other FIC-funded training programs in Nigeria and sub-Saharan Africa (South-South collaborative opportunities). V-BRCH represents the culmination of years of collaboration in research and training between Vanderbilt and AKTH and will lay the foundation for sustainable development of clinical trials research focused on HIV-associated NCDs in Nigeria.